Hm Payson & CO Denali Therapeutics Inc. Transaction History

Hm Payson & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$29.0 - $47.27 $16,762 - $27,322	-578 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$42.59 - $55.02 $24,617 - $31,801	578 New	578 $26,000
Q2 2021 Aug 17, 2021	SELL	$50.3 - $78.44 $50,953 - $79,459	-1,013 Closed	0 $0
Q4 2020 Mar 10, 2021	SELL	$36.89 - $93.56 $8,742 - $22,173	-237 Reduced 18.96%	1,013 $85,000
Q3 2020 Dec 21, 2020	BUY	$23.13 - $38.84 $28,912 - $48,550	1,250 New	1,250 $45,000

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Hm Payson & CO, based on Form 13F filings with the SEC.

Stay updated on Hm Payson & CO with notifications on news.